Market capitalization | $2.16b |
Enterprise Value | $1.96b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.64 |
P/S ratio (TTM) P/S ratio | 7.32 |
P/B ratio (TTM) P/B ratio | 4.40 |
Revenue growth (TTM) Revenue growth | 25.37% |
Revenue (TTM) Revenue | $295.21m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
12 Analysts have issued a Twist Bioscience Corp. forecast:
12 Analysts have issued a Twist Bioscience Corp. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 295 295 |
25%
25%
|
|
Gross Profit | 120 120 |
32%
32%
|
|
EBITDA | -153 -153 |
12%
12%
|
EBIT (Operating Income) EBIT | -186 -186 |
15%
15%
|
Net Profit | -220 -220 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The company also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. Twist Bioscience was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Emily Leproust |
Employees | 919 |
Founded | 2013 |
Website | www.twistbioscience.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.